NBIX - Neurocrine Biosciences, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
San Diego,
United States
Type: Equity
NBIX price evolution
NBIX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $139.7 | $396.3 | $251.1 | |
| Short term investments | $899.2 | $814.3 | $780.5 | |
| Net receivables | $481.1 | $468.2 | $450.7 | $439.3 |
| Inventory | $45.8 | $42.5 | $37.2 | $38.3 |
| Total current assets | $1876.6 | $1669.8 | $1799 | $1607 |
| Long term investments | $781.4 | $863.9 | $849.4 | |
| Property, plant & equipment | $337.3 | $343 | $346.1 | $347.3 |
| Goodwill & intangible assets | $33.5 | $34.3 | $35.5 | |
| Total noncurrent assets | $1635.2 | $1673.4 | $1644.4 | |
| Total investments | $1680.6 | $1678.2 | $1629.9 | |
| Total assets | $3535 | $3305 | $3472.4 | $3251.4 |
| Current liabilities | ||||
| Accounts payable | $277.3 | $358.5 | $417.2 | $448.8 |
| Deferred revenue | ||||
| Short long term debt | $259 | $170.1 | ||
| Total current liabilities | $429.7 | $398.5 | $712.9 | $654.8 |
| Long term debt | $256.2 | $252.9 | $258.3 | |
| Total noncurrent liabilities | $397.3 | $373.4 | $364.6 | |
| Total debt | $256.2 | $511.9 | $428.4 | |
| Total liabilities | $816.1 | $795.8 | $1086.3 | $1019.4 |
| Shareholders' equity | ||||
| Retained earnings | $81.1 | -$48.7 | -$113.7 | -$157.1 |
| Other shareholder equity | $14.5 | $2.5 | $3.3 | $7 |
| Total shareholder equity | $2509.2 | $2386.1 | $2232 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $251.1 | $262.9 | $340.8 | $190.3 |
| Short term investments | $780.5 | $726.4 | $370.5 | $613.9 |
| Net receivables | $439.3 | $350 | $185.5 | $157.1 |
| Inventory | $38.3 | $35.1 | $30.5 | $28 |
| Total current assets | $1607 | $1453.5 | $972.8 | $1016.2 |
| Long term investments | $849.4 | $401.5 | $624.4 | $265.3 |
| Property, plant & equipment | $347.3 | $145.6 | $155.8 | $127.4 |
| Goodwill & intangible assets | $35.5 | $37.2 | ||
| Total noncurrent assets | $1644.4 | $915.2 | $1099.7 | $718.5 |
| Total investments | $1629.9 | $1127.9 | $994.9 | $879.2 |
| Total assets | $3251.4 | $2368.7 | $2072.5 | $1734.7 |
| Current liabilities | ||||
| Accounts payable | $448.8 | $235.7 | $225.8 | $168.7 |
| Deferred revenue | ||||
| Short long term debt | $170.1 | $169.4 | ||
| Total current liabilities | $654.8 | $537.7 | $245.8 | $186.5 |
| Long term debt | $258.3 | $93.5 | $440.4 | $412.3 |
| Total noncurrent liabilities | $364.6 | $123.2 | $452.7 | $422 |
| Total debt | $428.4 | $262.9 | $440.4 | $412.3 |
| Total liabilities | $1019.4 | $660.9 | $698.5 | $608.5 |
| Shareholders' equity | ||||
| Retained earnings | -$157.1 | -$406.8 | -$635.8 | -$725.4 |
| Other shareholder equity | $7 | -$7.9 | -$1.7 | $1.8 |
| Total shareholder equity | $2232 | $1707.8 | $1374 | $1126.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $622.1 | $590.2 | $515.3 | $515.2 |
| Cost of revenue | $9.2 | $7.5 | $8.5 | |
| Gross Profit | $614.1 | $581 | $507.8 | $506.7 |
| Operating activities | ||||
| Research & development | $191.1 | $159.4 | $137.5 | |
| Selling, general & administrative | $242 | $243.1 | $218.9 | |
| Total operating expenses | $429.3 | $435.6 | $408.5 | $356.4 |
| Operating income | $145.4 | $99.3 | $150.3 | |
| Income from continuing operations | ||||
| EBIT | $98.6 | $35.6 | $199.3 | |
| Income tax expense | $60.5 | $33.6 | -$8.9 | $50.5 |
| Interest expense | $6.5 | $1.1 | $1.1 | |
| Net income | ||||
| Net income | $129.8 | $65 | $43.4 | $147.7 |
| Income (for common shares) | $65 | $43.4 | $147.7 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1887.1 | $1488.7 | $1133.5 | $1045.9 |
| Cost of revenue | $39.7 | $23.2 | $14.3 | $10.1 |
| Gross Profit | $1847.4 | $1465.5 | $1119.2 | $1035.8 |
| Operating activities | ||||
| Research & development | $565 | $463.8 | $328.1 | $275 |
| Selling, general & administrative | $887.6 | $752.7 | $583.3 | $433.3 |
| Total operating expenses | $1596.5 | $1216.5 | $1016.7 | $872.8 |
| Operating income | $250.9 | $249 | $102.5 | $163 |
| Income from continuing operations | ||||
| EBIT | $336.7 | $221 | $127.2 | $139.5 |
| Income tax expense | $82.4 | $59.4 | $11.8 | -$300.6 |
| Interest expense | $4.6 | $7.1 | $25.8 | $32.8 |
| Net income | ||||
| Net income | $249.7 | $154.5 | $89.6 | $407.3 |
| Income (for common shares) | $249.7 | $154.5 | $89.6 | $407.3 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $65 | $43.4 | $147.7 | |
| Operating activities | ||||
| Depreciation | $7.3 | $6.2 | $5.7 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $43.1 | $44.5 | $38.1 | |
| Total cash flows from operations | $64.6 | $130.3 | $123.5 | |
| Investing activities | ||||
| Capital expenditures | -$11.6 | -$11.2 | -$5.4 | |
| Investments | -$16.6 | -$43.8 | -$196.4 | |
| Total cash flows from investing | -$58.5 | -$28.2 | -$55 | -$201.8 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.8 | $69.9 | $35.4 | |
| Net borrowings | -$308.8 | |||
| Total cash flows from financing | -$196.7 | -$293 | $69.9 | $35.4 |
| Effect of exchange rate | $0.3 | $0.3 | ||
| Change in cash and equivalents | $98 | -$256.6 | $145.2 | -$42.6 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $249.7 | $154.5 | $89.6 | $407.3 |
| Operating activities | ||||
| Depreciation | $21.3 | $15.6 | $10.9 | $8.6 |
| Business acquisitions & disposals | -$42.7 | |||
| Stock-based compensation | $194.3 | $173.1 | $134.2 | $100 |
| Total cash flows from operations | $389.9 | $339.4 | $256.5 | $228.5 |
| Investing activities | ||||
| Capital expenditures | -$28.3 | -$16.5 | -$23.4 | -$10.9 |
| Investments | -$438.8 | -$117.9 | -$106.8 | $15 |
| Total cash flows from investing | -$467.1 | -$177.1 | -$130.2 | $4.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $65.3 | $44.7 | $27.5 | $29.1 |
| Net borrowings | -$279 | -$0.1 | -$186.9 | |
| Total cash flows from financing | $65.3 | -$234.3 | $27.4 | -$157.8 |
| Effect of exchange rate | $0.3 | -$1.3 | ||
| Change in cash and equivalents | -$11.6 | -$73.3 | $153.7 | $74.8 |
News
Fundamentals
| Market cap | $14.91B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 101.20M |
| Revenue | $2.24B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $385.90M |
| Revenue Q/Q | 24.72% |
| Revenue Y/Y | 25.72% |
| P/E ratio | 38.65 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.65 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $3.81 |
|---|---|
| ROA | 11.38% |
| ROE | N/A |
| Debt/Equity | 0.46 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.37 |
| Quick ratio | 4.26 |